课题基金 / 基金详情

Massaging brain vessels with vasomotion: Targeting the vasculature to alter disease progression in mouse models of dementia.

Massaging brain vessels with vasomotion: Targeting the vasculature to alter disease progression in mouse models of dementia.
通过血管舒缩按摩脑血管:靶向血管系统以改变痴呆小鼠模型的疾病进展。
批准号:
MR/X003418/1
负责人:
Jason Berwick
金额:
$129.01万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

Jason Berwick的其他基金

相似基金

相关文献

中文摘要
翻译
我们目前还没有可以阻止甚至延缓阿尔茨海默氏症的治疗方法。自20世纪80年代以来,S的大部分研究都集中在了解大脑中被称为β-淀粉样蛋白和Tau的蛋白质的作用。每个人一整天都会在大脑中产生这些蛋白质,但在健康人的大脑中,它们被移除了。在阿尔茨海默氏症中,这些蛋白质的清除出现了问题,随着时间的推移,它们开始积累。最终,它们会导致脑神经细胞死亡,这就是阿尔茨海默病的症状第一次显现的时候。尽管投入了数百万英镑的资金来研究这两种蛋白质是如何积累以及如何去除它们的,但我们仍然没有一种可以影响疾病速度或结果的治疗方法。最近,关于这种情况的其他理论也开始被研究。其中之一表明,大脑中的血液流动可能是一个重要因素。众所周知,与健康受试者相比,阿尔茨海默氏症患者的大脑血流水平通常较低。一般认为,这是由于大脑中的神经元因上述蛋白质的积聚而死亡。然而,科学家们现在开始调查可能是血流减少导致了这种情况。中心思想是,血液流动不仅能提供能量,还能有效地清洗大脑中产生的所有废物。如果血流量降到一定水平以下,可能只比正常水平低5%或10%,洗涤效率就会降低,废物(以蛋白质的形式)就会积累起来。据认为,这些血流变化发生在病情的早期,因此,如果能够开发出一种治疗方法来防止这种血流变化,就可以挽救更大比例的脑细胞。在过去的几年里,我们的研究团队一直在研究患有阿尔茨海默病的小鼠的大脑中的血液流动。这些小鼠是在已知在生命很早就患上阿尔茨海默氏症的人类身上发生基因变化的情况下培育出来的,这种情况被称为家族性形式。这些小鼠过度产生β-淀粉样蛋白,记忆缺陷与人类相似,对我们的项目至关重要的是,与没有这种疾病的动物相比,已知它们大脑中的血液流动水平较低。该项目的主要目的是通过提高整个基线或使血液流动振荡来改变阿尔茨海默病小鼠的大脑血液流动。这种振荡被称为血管运动,据信它可能会主动按摩脑血管,促进有毒蛋白质的清除。我们将通过两种不同的方法来改变大脑中的血液流动。第一种方法是使用一种名为光遗传学的技术精确激活脑细胞。这种方法的工作原理是将被称为视蛋白的蛋白质插入小鼠大脑中特定类别的神经元中。一旦这些视蛋白就位,我们就可以向动物的大脑照射蓝光,使目标细胞变得活跃。我们最近发表的工作和在这项应用中显示的试点数据表明,刺激这些神经元可以有力地增加血流量和血管运动。第二种方法被称为高碳酸血症,在这些实验中,小鼠呼吸室内空气中添加了少量二氧化碳(5%),这也被证明可以增加血液流量和血管舒缩。脑血流量与神经活动之间的机制逐渐崩溃,可能是导致许多脑部疾病的一个重要原因,甚至可能是正常衰老时出现的认知能力下降。这项拟议的项目寻求在原则上确定增加脑血流的治疗是否可以有效地减缓或阻止阿尔茨海默病相关症状在小鼠模型中的发展。如果成功,这可能会导致针对这种毁灭性疾病开发新的基于血管的疗法。
英文摘要
We currently have no treatment that stops or even slows down Alzheimer's disease. Most research since the 1980's has focussed on understanding the role of proteins in the brain called beta-amyloid and Tau. Everybody produces these proteins in their brains throughout the day, but in healthy people they are removed from the brain. In Alzheimer's disease, something goes wrong with the clearance of these proteins and they start to build up over time. Eventually they cause brain nerve cells to die and this is when the symptoms of Alzheimer's disease first become apparent. Despite millions of pounds in funding being invested into how these two proteins build up and ways to remove them, we still do not have a treatment that can affect disease speed or outcome. Recently, other theories about the condition have started to be investigated. One of these suggests that blood flow in the brain may be an important factor. It is well known that patients with Alzheimer's often have lower levels of blood flow in their brains compared to healthy subjects. It was generally assumed that this was due to neurons in the brain dying because of the build-up of the proteins mentioned above. However, scientists are now starting to investigate the potential that it is the reduction in blood flow that is causing the condition. The central idea is that blood flow not only serves to provide energy but also effectively washes the brain of all the waste it produces. If blood flow drops below a certain level, which may be only 5 or 10% less than normal, the washing is less efficient and the waste (in the form of proteins) builds up. It is thought that these changes in blood flow happen very early in the condition, therefore if a treatment can be developed to prevent this blood flow change, a greater proportion of the brain cells can be saved. For the last few years, our research team has been investigating blood flow in the brains of mice that have Alzheimer's Disease. These mice are bred with genetic changes known to occur in humans who get Alzheimer's very early in life, known as the familial form of the condition. These mice over produce beta-amyloid protein and have similar memory deficits to those seen in humans and, critically for our project, are known to have a lower level of blood flow in their brains compared to animals without the condition. The main aim of this project is to change blood flow in the brains of mice with Alzheimer's disease by either raising the entire baseline or causing blood flow to oscillate. This oscillation is termed vasomotion and it is believed that it might actively massage the brain blood vessels and improve clearance of the toxic proteins. We are going to change blood flow in the brain by two distinct methods. The first is by precise activation of brain cells using a technique called optogenetics. This method works by inserting proteins called opsins into a specific class of neuron in the mouse brain. Once these opsins are in place, we can shine a blue light onto the animal's brain causing the targeted cells to become active. Our recently published work and pilot data shown in this application has shown that stimulation of these neurons robustly increases blood flow and vasomotion. The second method is called hypercapnia, in these experiments the mouse breathes in room air with a small amount of carbon dioxide added (5%), again this has been shown to increase blood flow and vasomotion. A gradual breakdown in the mechanism matching brain blood flow to neural activity may be an important contributory cause of many brain diseases, maybe even the cognitive decline seen in normal aging. The proposed project seeks to establish in principle whether a treatment that increases brain blood flow can effectively slow or block the development of Alzheimer's Disease-associated symptoms in mouse models of the disease. If successful, this could lead to new vascular-based therapies to be developed for this devastating disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.cccb.2023.100189
发表时间: 2023
期刊: CEREBRAL CIRCULATION-COGNITION AND BEHAVIOR
影响因子: --
作者: [Sri, Sarmi, Greenstein, Adam, Granata, Alessandra, Collcutt, Alex, Jochems, Angela C C, McColl, Barry W, Castro, Blanca Diaz, Webber, Caleb, Reyes, Carmen Arteaga, Hall, Catherine, Lawrence, Catherine B, Hawkes, Cheryl, Pegasiou-Davies, Chrysia-Maria, Gibson, Claire, Crawford, Colin L, Smith, Colin, Vivien, Denis, McLean, Fiona H, Wiseman, Frances, Brezzo, Gaia, Lalli, Giovanna, Pritchard, Harry A T, Markus, Hugh S, Bravo-Ferrer, Isabel, Taylor, Jade, Leiper, James, Berwick, Jason, Gan, Jian, Gallacher, John, Moss, Jonathan, Goense, Jozien, McMullan, Letitia, Work, Lorraine, Evans, Lowri, Stringer, Michael S, Ashford, Mlj, Abulfadl, Mohamed, Conlon, Nina, Malhotra, Paresh, Bath, Philip, Canter, Rebecca, Brown, Rosalind, Ince, Selvi, Anderle, Silvia, Young, Simon, Quick, Sophie, Szymkowiak, Stefan, Hill, Steve, Allan, Stuart, Wang, Tao, Quinn, Terry, Procter, Tessa, Farr, Tracy D, Zhao, Xiangjun, Yang, Zhiyuan, Hainsworth, Atticus H, Wardlaw, Joanna M]
通讯作者: Wardlaw, Joanna M
Investigating the thermoregulatory role of neurovascular coupling and the anti-epileptogenic and neuroprotective effects of focal cerebral cooling
  • 批准号:
    MR/M013553/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $56.49万
  • 财政年份:
    2015
  • 负责人:
    Jason Berwick
  • 依托单位:
The neurophysiological basis of prolonged negative BOLD signals
  • 批准号:
    G1002194/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $71.08万
  • 财政年份:
    2011
  • 负责人:
    Jason Berwick
  • 依托单位:
Neurovascular coupling under the microscope
  • 批准号:
    G0601581/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $45.4万
  • 财政年份:
    2007
  • 负责人:
    Jason Berwick
  • 依托单位:
国内基金
海外基金
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    汪雪玲
  • 依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    万杰清
  • 依托单位:
KLK10调控胶质—血管耦合与对话促缺血性卒中后血脑屏障修复的机制
  • 批准号:
    82371465
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李龙宣
  • 依托单位:
Sitagliptin通过microbiota-gut-brain轴在2型糖尿病致阿尔茨海默样变中的脑保护作用机制
  • 批准号:
    81801389
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2018
  • 负责人:
    田茗源
  • 依托单位: